MedPath

Risico op en oorzaken van abnormaal menstrueel bloedverlies in vrouwelijke proefpersonen in de vruchtbare leeftijd met trombosebeen of longembolie

Recruiting
Conditions
Venous thromboembolismMenstrual bleedingAnticoagulation
Registration Number
NL-OMON24079
Lead Sponsor
niversity of Leiden
Brief Summary

one

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
Not specified
Target Recruitment
210
Inclusion Criteria

Consecutive female patients between the ages of 18 and 50 with child bearing potential and objectivated, symptomatic VTE, who fulfil all the inclusion criteria and meet none of the exclusion criteria, are eligible for inclusion.

Exclusion Criteria

1)Woman between the ages of 18 and 50 who were subjected to hysterectomy or chemically induced menopause;

Study & Design

Study Type
Observational non invasive
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Incidence of new-onset abnormal menstrual bleeding
Secondary Outcome Measures
NameTimeMethod
1)Rate of clinical relevant non-major and major (menstrual) bleeding according to the ISTH criteria;<br /><br>2)Change in rate of abnormal menstrual bleeding after diagnosis of VTE after initiation of anticoagulants, and during the follow-up period;<br /><br>3)Impact of new-onset abnormal menstrual bleeding on QoL as assessed with the MBQ, VEINS-QOL and PEmb-QoL;<br /><br>4)Predictors of new-onset abnormal menstrual bleeding;<br /><br>5)Changes in contraceptive measures during the study: details, incidence, causes and effect on primary endpoint and recurrent VTE;<br /><br>6)Changes in anticoagulation therapy: details, incidence, causes and effect on primary endpoint and recurrent VTE; <br /><br>7)Presence of underlying gynaecological or other morbidities as explanation for abnormal menstrual bleeding.
© Copyright 2025. All Rights Reserved by MedPath